Prenatal exposure to acid suppressor medications and development of ductus arteriosus in term newborn.

OBJECTIVE: The ductus arteriosus normally closes after birth. Histamine2 Receptor Antagonist (H2RA) has been associated with patent ductus arteriosus (PDA). We aimed to study the characteristics of term infants with PDA and their possible association with prenatal exposure to antacids - Proton Pump Inhibitors (PPI) and H2RA.

STUDY DESIGN: Population-based matched case-control study of mothers registered at "Clalit" Health Maintenance Organization (HMO) and their infants born at "Soroka" University Medical Center (SUMC) between 2001-2018. Cases are defined as term infants born with PDA diagnosed by echocardiography and registered in the post-delivery discharge form. Each case was matched with four term newborns without PDA diagnosis. Exposure window was defined by the timing of first purchase of H2RA or PPI during pregnancy and based on information from a computerized medication database (Clalit HMO, SUMC) Results. PDA was diagnosed in 1,884 term infants (4.9%). Characteristics included a significantly higher percentage of lack of prenatal care, cesarean section, in vitro fertilization, polyhydramnios, oligohydramnios, Apgar 1 minute <5, and prenatal exposure to H2RA (OR4.18) and PPIs (OR3.50) (all p<0.001). PDA association with exposure window was similar in each trimester (1.5-2%) for both H2RA and PPI.

CONCLUSION: PDA Incidence in term infants in our population was greater than previously reported. PPI and H2RA are both anti-acids with different mechanisms of action. The similar OR for exposure to one as well as the other, and the lack of influence of the initial exposure period, are compatible with bias.